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Abstract
Background: Fast-track colonoscopy to detect patients with colorectal cancer based on high-risk symptoms is
associated with low sensitivity and specificity. The aim was to derive a predictive score of advanced colonic
neoplasia in symptomatic patients in fast-track programs.
Methods: All patients referred for fast-track colonoscopy were evaluated. Faecal immunological haemoglobin test
(3 samples; positive> 4 μg Hb/g), and a survey to register clinical variables of interest were performed. Colorectal
cancer and advanced adenoma were considered as advanced colonic neoplasia. A sample size of 600 and 500
individuals were calculated for each phase 1 and phase 2 of the study, respectively (Phase 1, derivation and Phase
2, validation cohort). A Bayesian logistic regression analysis was used to derive a predictive score.
Results: 1495 patients were included. Age (OR, 21), maximum faecal-Hb value (OR, 2.3), and number of positive
samples (OR, 28) presented the highest ORs predictive of advanced colonic neoplasia. The additional significant
predictive variables adjusted for age and faecal-Hb variables in Phase 1 were previous colonoscopy (last 5 years)
and smoking (no, ex/active). With these variables a predictive score of advanced colonic neoplasia was derived.
Applied to Phase 2, patients with a Score > 20 had an advanced colonic neoplasia probability of 66% (colorectal
cancer, 32%), while those with a Score ≤ 10, a probability of 10% (colorectal cancer, 1%). Prioritizing patients with
Score > 10, 49.4% of patients would be referred for fast-track colonoscopy, diagnosing 98.3% of colorectal cancers
and 77% of advanced adenomas.
Conclusions: A scoring system was derived and validated to prioritize fast-track colonoscopies according to risk,
which was efficient, simple, and robust.
Keywords: Colorectal cancer, Advanced adenoma, Faecal immunological occult haemoglobin test, Fast-track
colonoscopy
Background
Colorectal cancer (CRC) is the third most common malig-
nancy in men and the second most common in women,
and the fourth leading cause of cancer-related deaths
worldwide [1]. Despite progress made in recent years in
the diagnosis and treatment of this disease, a significant
improvement in survival at 5 years has not been shown,
which persists around 50%. This is because over 80% of
new cases are symptomatic patients, and the disease is ad-
vanced at the time of diagnosis. A significant percentage
of CRC patients are diagnosed based on the presence of
clinical symptoms associated with this malignancy [2–5].
It is therefore important to identify patients who have
symptoms and/or signs of suspicion, so an early colonos-
copy can be indicated. Recently, the proposed rule of 2-
week wait (2WW) referral system for the NHS (UK) has
been re-evaluated [6]. This system was proposed in 2000
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to ensure that specialists in reference hospitals assess all
patients with suspected CRC within 14 days after urgent
referral by a primary care physician. This approach is
based on the guidelines of the National Institute for
Health and Care Excellence (NICE) criteria for suspected
cancer [7]. However, different studies have shown the low
sensitivity and specificity of the NICE criteria to refer for a
2WW program [8–11]. Although 77% of patients with
CRC are referred by primary care physicians via urgent
pathways, this system did not improve 5-year colorectal
cancer survival [12]. This finding may be due to the fact
that the symptoms when present very often indicate an
advanced disease, and once a cancer became symptomatic,
early treatment did not improve survival. Besides, the
2WW rule has been criticized, because of the low overall
cancer detection rate, due to the poor specificity of the pa-
tient clinical symptoms (common with benign bowel dis-
eases), resulting in overwhelming referral rates. The new
NICE guidelines (July 2017) suggest using faecal occult
blood test for clinical symptoms associated with a low
probability of having CRC (PPV < 3%).
In this scenario, a number of CRC prediction models
have been designed and validated in different settings
[13]. These prediction models are calculated from math-
ematical equations based mainly on symptoms [14–16],
and recently also on 1-sample faecal immunological test
(FIT) [11, 17]. The patients included in those studies
were symptomatic, but they did not always fulfil the cri-
teria for a fast-track program. The diagnostic accuracy
of these risk-scoring models is generally considered sat-
isfactory and better than the existing referral criteria,
but at present, they have not been widely recommended,
perhaps as a consequence of the complicated mathemat-
ical equations required for their calculation.
In spite that a meta-analysis showed that in average-
risk asymptomatic patients increasing the number of
FIT samples did not affect the pooled performance char-
acteristics of FITs for CRC [18], recent studies suggested
that in symptomatic patients using either 2 or 3 tests
provided the best discrimination for CRC [19–23].
Thus, the aim of the study was to derive and validate a
predictive risk score to determine the pre-test-probability
of advanced colonic neoplasia (ACN) in symptomatic
patients with indication of a fast-track colonoscopy. In
addition, to assess the accuracy for ACN diagnosis of a 3-
sample FIT as compared to 1-sample FIT.
Methods
The study protocol is available as a supplementary file
(Additional file 1).
Study population
All patients in the fast-track colonoscopy programs for
CRC in the three participating hospitals were included
in the period March-2014 to September-2016. Health-
care areas of these hospitals comprise a population of
about 917,905 inhabitants. Patients with high-risk symp-
toms for CRC were sent for a full colonoscopy following
the government’s program to expedite the diagnosis of
CRC. All the colonoscopies in the health areas involved
are performed at the endoscopic units of the three cen-
tres. Each unit performed more than 3,000 colonos-
copies a year. Fast-track colonoscopy was requested
mainly from primary care physicians or gastroenterology
specialists in primary care medicine, but also from the
hospital outpatient visits (different medical and surgical
specialties). Inclusion criteria were as follows: 1. Age of
18 years or more; 2. Fulfilment of the criteria for a fast-
track colonoscopy based on NICE guidelines [7]; 3. Sign-
ing informed consent. The exclusion criteria included
pregnancy, asymptomatic individuals who were undergo-
ing colonoscopy for CRC screening, patients with a
previous history of colonic disease scheduled for a sur-
veillance colonoscopy, patients requiring hospital admis-
sion, and patients whose symptoms had ceased within
the three months before evaluation.
The clinical research ethics committees of the three
centres approved the study and patients provided writ-
ten informed consent.
Interventions
Trained case managers (specialized nurses) conducted
the patients’ personal interviews to assure a standardized
and proper collection of faecal samples, the fulfilment of
the inclusion and exclusion criteria, and the signing of
informed consent. In all patients the following interven-
tions were performed: 1. FIT on three different days in
the week prior to colonoscopy; and 2. A patient consult-
ation questionnaire including a detailed assessment of
colorectal symptoms, personal and family history of
polyps/CRC, smoking and consumption of medication
increasing the risk of a gastrointestinal haemorrhage
(NSAIDs, aspirin, anticoagulants). In the case of rectal
bleeding, patients were instructed, if possible, to collect
faecal samples on days that they did not have rectal
bleeding. Faecal haemoglobin was analysed using iFOB
kit (Linear Chemicals SL, Barcelona, Spain) (see detailed
description of the test in Additional file 2) which is able
to detect values of 4 μg Hb/g faeces. Quantitative values
were recorded for each of the three samples from 4 to
higher than 160 μg Hb/g faeces.
A full colonoscopy with iv sedation with colon biopsies
and/or polypectomy, if necessary, was performed on all
evaluated patients. Endoscopists involved in the study had
more than 2 years of experience from routine clinical col-
onoscopies, undertaking at least 200 procedures per year,
with caecal intubation rates over 97%. The cleaning degree
(Boston scale), results of the exploration, and pathology
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studies were registered. Colonoscopies with insufficient
preparation (Boston scale = 1 or less in one colonic seg-
ment) were repeated. In the case of multiple polyps, the
number of polyps, the size of the largest, and the most ad-
vanced pathology were registered. If CRC was recognized,
its stage (TNM classification) and location (right, trans-
verse, or left colon) was recorded.
Main outcome
The main outcome was ACN detection, which was de-
fined as the presence of CRC or advanced adenoma (AA)
(> 1 cm or high-grade dysplasia or villous component).
Intramucosal carcinoma (Tis) was considered as AA.
Derivation and validation cohort
The rule of thumb of 10 events per variable was used to
obtain a derivation cohort, assuming that the logistic re-
gression model may account for between 10 and 15
dummy predictor variables [24]. In this line, assuming a
prevalence of ACN of 20% (8% CRC, 12% AA) [25], a
minimum sample size cohort of 600 individuals was re-
quired (expected events of 120). During the timeline of
the study (March-2014 to May-2015) we could derive a
larger cohort of N = 761 individuals in order to guaran-
tee the number of dummy variables. From these individ-
uals FIT was not available in 30 out of them, leading to
a final cohort of N = 731 individuals.
We settled that a minimum sample size of 500 was re-
quired for the validation phase (see Additional file 3). Fi-
nally, we recruited a cohort of 527 individuals. In
addition, symptomatic patients with no indication for a
fast-track colonoscopy and negative FIT were included,
to have enough patients with negative FIT in the low-
risk group (finally, 136 in phase 1 and 101 in phase 2).
This totals 867 individuals in phase 1 (731 + 136) with
171 events (104 advanced adenomas and 67 colorectal
cancers), and 628 individuals in phase 2 (527 + 101) with
148 events (99 AA and 49 CRC) (Fig. 1).
Derivation of the FIT variables included in the model
Three samples for FIT were obtained in each of the N =
867 individuals and we used the maximum f-Hb value
(MAXFIT) out of the three samples in each individual.
Since the variable f-Hb did not follow a Normal distribu-
tion even after logarithmic transformation, as has been
reported elsewhere [17], and the risk of CRC did not
have a linear relationship to f-Hb, MAXFIT was intro-
duced as a categorical variable. We selected as cut-off
11 μg Hb/g faeces (see Additional file 3). Therefore, we
assumed three categories for the MAXFIT variable: ≤4,
> 4 to 11, > 11 μg Hb/g faeces. In addition, since we col-
lected three faecal samples, we also used a variable
which counts the number of samples with FIT> 4 μg Hb/
g faeces (NSAMPLES> 4). This variable could take
values in the range from 0 to 3 and was introduced in
the model as an interaction term with MAXFIT variable.
Development of the risk score
Univariate analysis was carried out on the derivation set
using the Pearson chi-square method to examine the asso-
ciation between clinical risk factors and advanced neopla-
sia. In our study, age and MAXFIT were the variables
associated with higher ORs in the univariate analyses (see
Tables 1 and 2), and it is in accordance with results re-
ported in previous studies [17]. Unlike other studies, we
have also considered the number of positive samples,
since this variable improved the predictive performance of
the model. Thus, the prognostic variables included in the
seminal multivariate logistic model were Age, MAXFIT
and NSAMPLES> 4. Then, significant variables in the
Fig. 1 Diagram flow of participants through the study in both the derivation and validation cohorts, including the number of participants with
the main outcome
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univariate analysis (p < 0.05) were introduced one by one
into the seminal multivariate model and its C-Statistic and
Brier score were recorded. Those variables that signifi-
cantly improved the performance indexes (higher C-Stat-
istic and lower Brier score) compared against the seminal
values were chosen to be included in the final prognostic
model (see Table 4). For each risk factor, we assigned a
weight in the risk score using the respective odds ratio
(OR) yielded by the logistic regression, where the max-
imum log-OR received a score of 10 points. The risk score
for an individual was the sum of their individual risk fac-
tors. Risk groups were classified according to the ‘AddFor’
algorithm, which allows for categorization of continuous
variables in prediction models within a logistic regression
model, in such a way that the best discriminative ability is
obtained in terms of the highest C-Statistic [26]. This
methodology allows for the selection of more than one cut
point and better risk classification of patients.
Statistical analysis
The development and external validation of a multivari-
able prediction model study was designed according to
TRIPOD statement [27]. A checklist indicating the pages
where information for each item is reported can be
found as a supplementary file (Additional file 4).
Statistical analysis was performed with R software [28].
Variables considered after variable selection in univariate
analysis are listed in Tables 1 and 2. Other analysed
variables such as family or personal history of CRC or
colonic polyps were no informative. Missing-data were
introduced as ‘Unknown’ and analysed as a new category
of each variable; this was mainly observed for analytical
variables related to iron deficiency since at inclusion
many patients had received oral iron supplements.
A Bayesian logistic regression model accounting for
age and NSAMPLES> 4 depending on the levels of
MAXFIT was fitted to each one of the variables consid-
ered, assuming a non-informative Cauchy prior for the
model parameters [29]. Once the model was fitted, we
derived the median OR and their 95% credible interval
from the subsequent distribution of the model parame-
ters. The C-Statistic and the Brier score were used as the
overall performance measures of the modelling [30],
selecting the model with maximum C-Statistic and mini-
mum Brier score. Finally, the Hosmer-Lemeshow test
was used to test the calibration of the model in the val-
idation cohort [24, 30].
To assess the effect of using 3-sample FIT as com-
pared to 1-sample FIT, we developed different models
created with a FIT value randomly chosen from the 3
values of each patient. Also we compared the 3-sample
FIT final model with a previously published 1-sample
FIT test score (FAST score) [17]. For these comparisons
we used the method proposed by DeLong et al. [31], as
implemented by Robin et al. in pROC package [32].
Results
Description of the derivation and validation cohorts
Between April 2014 and February 2017, 1538 patients
were included, 897 in the derivation (phase 1) and 641 in
the validation (phase 2) cohorts (Fig. 1). Another 1595 pa-
tients either did not agree to participate or were not con-
tacted with enough time before the colonoscopy. There
were no differences in demographic characteristics and in-
dications for colonoscopy between these and the included
patients (data not shown). Forty-three patients (2.8%)
were excluded because of improper FIT collection. The in-
dications for colonoscopy and the baseline characteristics
Table 1 Crude and adjusted ORs of age and FIT variables for association with ACN in the derivation (Phase I) cohort (Seminal
model: C-Statistic = 0.846; Brier Score = 0.115; Hosmer-Lemeshow p-value = 0.796)
X Control group (non-AA, non-CRC) AA+CRC OR (Crude) OR (Adjusted)
Age group (years)
≤ 40 66 (9.48%) 1 (0.58%) Ref. Ref.
40–50 98 (14.1%) 6 (3.51%) 3.61 [0.58;94.9] 4.62 [0.49;43.6]
50–60 157 (22.6%) 34 (19.9%) 12.5 [2.63;299] 17.9 [2.25;142.4]
> 60 375 (53.9%) 130 (76.0%) 20.0 [4.42;469] 21.54 [2.8;165.6]
MAXFIT (out of 3 samples)
≤ 11 508 (73.0%) 33 (19.3%) Ref. Ref.
> 11 188 (27.0%) 138 (80.7%) 11.2 [7.49;17.3] 2.31 [0.99;5.38]
NSAMPLES> 4
0 441 (63.4%) 24 (14.0%) Ref. Ref.
1 110 (15.8%) 18 (10.5%) 3.01 [1.55;5.74] 2.98 [1.54;5.8]
2 71 (10.2%) 18 (10.5%) 4.65 [2.37;9.01] 4.49 [2.3;8.8]
3 74 (10.6%) 111 (64.9%) 27.2 [16.7;46.0] 28.1 [16.8;46.9]
MAXFIT: maximum f-Hb value; NSAMPLES > 4: Number of samples with FIT > 4 μg Hb/g faeces
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Table 2 Univariate and age- and FIT-adjusted predictors of ACN in the derivation (Phase I) cohort: Crude and adjusted ORs, and C-









N = 696 N = 171
Gender
Man 311 (44.7%) 103 (60.2%) Ref. Ref.
Woman 385 (55.3%) 68 (39.8%) 0.53 [0.38;0.75] 0.81 [0.53;1.21] 0.841 / 0.1158
Body Mass Index (Kg/m2)
≤ 25 246 (35.3%) 47 (27.5%) Ref. Ref.
> 25 450 (64.7%) 124 (72.5%) 1.44 [1.01;2.10] 1.19 [0.77;1.85] 0.841 / 0.1161
Colonoscopy (5 years before)
No 555 (79.7%) 153 (89.5%) Ref. Ref.
Yes 141 (20.3%) 18 (10.5%) 0.47 [0.27;0.77] 0.35 [0.21;0.63] 0.862 / 0.1031
Smoking (History)
No 359 (51.6%) 77 (45.0%) Ref. Ref.
Yes (Ex/Current) 337 (48.4%) 94 (55.0%) 1.30 [0.93;1.82] 1.51 [1.02;2.29] 0.859 / 0.1050
Smoking (Years):
No 359 (51.6%) 77 (45.0%) Ref. Ref.
≤ 42 191 (27.4%) 25 (14.6%) 0.61 [0.37;0.98] 1.17 [0.6;2.33]
> 42 146 (21.0%) 69 (40.4%) 2.20 [1.51;3.21] 1.65 [0.99;2.61] 0.849 / 0.1086
Drugs (NSAIDs or antiplatelet
or anticoagulants)
No 415 (59.6%) 98 (57.3%) Ref. Ref.
Yes 281 (40.4%) 73 (42.7%) 1.10 [0.78;1.54] 0.79 [0.52;1.21] 0.841 / 0.1153
Anticoagulants
No 673 (96.7%) 156 (91.2%) Ref. Ref.
Yes 23 (3.30%) 15 (8.77%) 2.82 [1.40;5.50] 1.67 [0.75;3.80] 0.842 / 0.1159
NSAIDs
No 525 (75.4%) 136 (79.5%) Ref. Ref.
Yes 171 (24.6%) 35 (20.5%) 0.79 [0.52;1.18] 0.79 [0.49;1.29] 0.846 / 0.1156
Abdominal pain
No 299 (43.0%) 97 (56.7%) Ref. Ref.
Yes 397 (57.0%) 74 (43.3%) 0.58 [0.41;0.81] 0.77 [0.52;1.16] 0.840 / 0.116
Iron deficiency
No 237 (34.1%) 56 (32.7%) Ref. Ref.
Yes 174 (25.0%) 55 (32.2%) 1.34 [0.88;2.04] 0.92 [0.55;1.92]
Unknown 285 (40.9%) 60 (35.1%) 0.89 [0.59;1.34] 0.86 [0.54;1.37] 0.840 / 0.116
Iron deficiency anaemia
No 371 (53.3%) 77 (45.0%) Ref. Ref.
Yes 166 (23.9%) 54 (31.6%) 1.57 [1.05;2.32] 1.13 [0.69;1.84]
Unknown 159 (22.8%) 40 (23.4%) 1.21 [0.79;1.85] 1.14 [0.69;1.91] 0.840 / 0.116
Type change bowel habit
No 261 (37.5%) 78 (45.6%) Ref. Ref.
Diarrhoea 226 (32.5%) 59 (34.5%) 0.87 [0.59;1.28] 1.08 [0.68;1.71]
Constipation 179 (25.7%) 31 (18.1%) 0.58 [0.36;0.91] 0.71 [0.42;1.22]
Unknown 30 (4.31%) 3 (1.75%) 0.35 [0.08;1.02] 0.78 [0.23;2.74] 0.840 / 0.1153
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of the patients included in each phase are shown in Add-
itional file 6 and Additional file 7. One thousand fifty-eight
patients met the NICE criteria for a fast-track colonoscopy
and 237 did not (136 in phase 1 and 101 in phase 2).
We detected CRC in 67/867 (7.7%) in study phase 1,
and 49/628 (7.8%) in phase 2. No patient of the sub-
group with negative FIT and who did not met the NICE
criteria for a fast-track colonoscopy had a CRC. There
were no significant differences in tumour localization
and staging between the two phases (Additional file 5).
Additionally, we found advanced adenomas in 203 pa-
tients, 104 (11.9%) in phase 1 (5 with no NICE criteria
and negative FIT) and 99 (15.7%) in phase 2 (6 with no
NICE criteria and negative FIT). Six adenomas in phase
1 had intramucosal carcinoma (Tis).
There were no significant differences in demographic
and clinical variables between phase 1 and phase 2 in-
cluded patients (Additional file 7). However, there were
significant differences in the FIT variables (MAXFIT and
NSAMPLES> 4). In fact, all CRC patients in phase 1 had
positive FIT with values above 11 μg Hb/g faeces. In
contrast, there were three CRC patients in phase 2 with
negative FIT, and two patients with values > 4 and <
11 μg Hb/g faeces. Overall, there were 6/116 (5%) CRC
patients with only 1 out of 3 faecal samples positive.
Derivation of the predictive risk score
Age and FIT variables were independently associated with
the risk of ACN, with ORs very much higher than other
variables (Table 1). Univariate and age- and FIT-adjusted
predictors of ACN in the derivation (Phase I) cohort are
presented in Table 2. Only ‘Colonoscopy up to 5 years be-
fore FIT’, ‘smoking history’, and ‘smoking years’ retained
overall statistical significance and improve C-Statistic and
Brier score of the multivariate analyses. Both in the deriv-
ation and the validation cohorts, the C-Statistic with
‘smoking history’ was slightly better; thus we selected this
simpler variable for the derived score. The derived
predictive risk score is described in Table 3, which shows
the multivariate predictors of ACN using the model fitted
to the derivation (Phase I) cohort. The predictive score
ranged from − 4 to 24 points. The predictive performance
Table 2 Univariate and age- and FIT-adjusted predictors of ACN in the derivation (Phase I) cohort: Crude and adjusted ORs, and C-










No 299 (43.0%) 97 (56.7%) Ref. Ref.
Yes, 1–12 Days 123 (17.7%) 26 (15.2%) 0.65 [0.40;1.05] 0.65 [0.37;1.15]
Yes, > 12 Days 274 (39.4%) 48 (28.1%) 0.54 [0.37;0.79] 0.86 [0.54;1.37] 0.850 / 0.1157
Rectal bleeding pattern
No 342 (49.1%) 84 (49.1%) Ref. Ref.
Yes, without specific pattern 219 (31.5%) 43 (25.1%) 0.80 [0.53;1.20] 0.59 [0.36;1.07]
Yes, with specific pattern 135 (19.4%) 44 (25.7%) 1.44 [0.97;2.12] 1.33 [0.87;2.01] 0.849 / 0.1151
Rectal bleeding duration (days)
No rectal bleeding 342 (49.1%) 84 (49.1%) Ref. Ref.
≤ 30 328 (47.1%) 74 (43.3%) 0.92 [0.65;1.30] 0.63 [0.41;1.05]
> 30 26 (3.74%) 13 (7.60%) 2.04 [0.97;4.10] 0.86 [0.37;1.98] 0.846 / 0.1150
Haemoglobin (g/dL)
≤ 11 105 (15.1%) 43 (25.1%) Ref. Ref.
> 11 481 (69.1%) 112 (65.5%) 0.57 [0.38;0.86] 1.02 [0.61;1.71]
Unknown 110 (15.8%) 16 (9.36%) 0.36 [0.18;0.67] 0.62 [0.31;1.31] 0.847 / 0.1127
Ferritin (ng/mL)
≤ 40 176 (25.3%) 56 (32.7%) Ref. Ref.
> 40 225 (32.3%) 53 (31.0%) 0.74 [0.48;1.13] 0.82 [0.51;1.34]
Unknown 295 (42.4%) 62 (36.3%) 0.66 [0.44;0.99] 0.85 [0.52;1.39] 0.849 / 0.1106
CEA (ng/mL)
≤ 12 610 (87.6%) 135 (78.9%) Ref. Ref.
> 12 5 (0.72%) 11 (6.43%) 9.73 [3.43;32.1] 2.91 [0.88;9.36]
Unknown 81 (11.6%) 25 (14.6%) 1.40 [0.85;2.25] 1.27 [0.71;2.27] 0.849 / 0.1101
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of the final risk score for ACN was excellent with a C-
Statistic of 0.865 (95% CI, 0.83–0.89). Taking into account
only CRC, the C-Statistic was 0.93 (95% CI, 0.91–0.95).
Effect of the number of positive samples on the
predictive performance of the model
We compared the model resulting from taking 1 random
sample out of the 3 samples with the proposed final
model for ACN which includes MAXFIT and NSAM-
PLES (Table 4). This was done 5 times. The C-Statistic
from the five random samples were lower than that of
the proposed final model, showing that the final model
including the interaction between MAXFIT and NSAM-
PLES classified better a 2.2–3% of patients.
In addition, we compared our 3-sample FIT final
model (COLONOFIT score) with the 1-sample FIT, age
and sex test (FAST) score developed by Cubiella et al.
[17] In study phase 1, the C-Statistic for both CRC and
ACN was significantly higher with COLONOFIT than
FAST score (CRC, 0.93 ± 0.009 vs. 0.90 ± 0.01; p = 0.04;
and ACN, 0.86 ± 0.02 vs. 0.82 ± 0.02; p = 0.0007) (Fig. 2).
In addition, in study phase 2, the C-Statistic for both
CRC and ACN was also higher with COLONOFIT than
FAST score (CRC, 0.86 ± 0.025 vs. 0.83 ± 0.03; p = 0.18;
and ACN, 0.79 ± 0.02 vs. 0.75 ± 0.02; p = 0.0034). The
differences between both scores were maintained after
excluding the patients who did not met NICE criteria
and had negative FIT (data not shown).
Reliability of the model in the validation cohort
As above mentioned, the risk-score was more accurate for
ACN and CRC detection in the derivation than in the
validation cohort. However, its performance remained
good. The Hosmer-Lemeshow p-value was 0.86, showing
that the model was well calibrated.
Patients of the validation cohort were categorized into
risk subgroups according the presence of ACN and the
value of the final risk-score using the ‘AddFor’ algorithm
(see methods) (Table 5). The probability (or prevalence)
of ACN for a risk-score > 20 points was 66%, whereas
for a risk-score ≤ 10 points it was 10%. If we take into
account only CRCs, these probabilities were 32 and 1%,
respectively.
A risk-score > 10 points allowed us to diagnose 96% of
CRC and 72% of AA, with only needing to prioritize a
50% of colonoscopies (Table 6). No patient with a risk-
score < 4 points had CRC but in this case we need to
prioritize 95% of colonoscopies. Higher cut-offs would
prioritize fewer colonoscopies while increasing the per-
centage of CRC loss.
Table 3 Multivariate predictors of ACN using the model fitted to the derivation (Phase I) cohort. The predictive score derived
ranged from −4 to 24 points (Final model: C-Statistic = 0.865; Brier Score = 0.10; Hosmer-Lemeshow p-value = 0.86)
Risk Factor OR Q 2.5 Q 97.5 Points
Age 40–50 years 2.26 0.52 10.05 3
Age 50–60 years 7.58 2.02 28.56 8
Age > 60 years 11.88 3.27 43.13 10
Colonoscopy (in the previous 5 years) (Yes) 0.36 0.2 0.65 −4
Smoking (Yes) 1.49 1.01 2.27 2
IF MAXFIT [> 4–11]
NSAMPLES> 4 1.72 1.04 2.83 2x†
IF MAXFIT > 11
NSAMPLES> 4 2.89 2.45 3.44 4x†
MAXFIT: maximum f-Hb value; NSAMPLES > 4: Number of samples with FIT > 4 μg Hb/g faeces. Discrete variable (0 to 3). Points: Points assigned to each
Risk Factor
†Note on 2x/4x: factor to multiply NSAMPLES
How do we interpret the model? Ex: Suppose a 55-year-old man has not smoked or has done a prior colonoscopy and with values of FIT 4, 6 and 10 μg Hb/g
faeces. This individual has a MAXFIT value of 10, and 2 samples with FIT > 4 (2 positive samples); therefore its score will be 8 points by age + 2 points per FIT
(corresponding to the OR = 1.72) multiplied by 2 positive samples, giving 4 points. Total: 12 points. But if their FIT values were 4, 8, and 12 μg Hb/g faeces, the
MAXFIT value of 12 and two positive samples, their score would be 8 points by age + 4 points per FIT (corresponding to the OR = 2.89) multiplied by 2 positive
samples, giving 8 points. Total: 16 points
Table 4 Comparison of the model resulting from taking 1
random sample out of the 3 FIT samples with the proposed
final model for ACN
MODEL AUC CI 95% (Bootstrap)
With interaction† 0.865 0.833–0.894
RANDOM – 1‡ 0.844 0.809–0.875
RANDOM – 2 0.835 0.800–0.897
RANDOM – 3 0.843 0.809–0.876
RANDOM – 4 0.842 0.808–0.875
RANDOM – 5 0.842 0.807–0.875
†Final model including MAXFIT and NSAMPLES
‡RANDOM-N: Model created with a FIT value randomly chosen from the 3
values of each patient. This was repeated 5 times
MAXFIT: maximum f-Hb value; NSAMPLES> 4: Number of samples with FIT >
4 μg Hb/g faeces
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Discussion
A multivariable prediction modelling study to assess the
pre-test-probability of ACN in symptomatic patients
with indication of a fast-track colonoscopy was per-
formed. This approach has been considered the most
efficient method of capturing the effects of clinical
judgement [33]. The derived and validated risk-score
(COLONOFIT score) may be useful to prioritize colon-
oscopies in patients fulfilling criteria for a fast-track ex-
ploration. We saw as more relevant both the percentage
of missed cases of CRC and the percentage of patients
to prioritize than sensitivity and specificity to detect
ACN. In fact, a risk-score > 10 points, which would
imply to prioritize 50% of eligible patients, allowed the
overall diagnosis of 98% of CRC (2% of missed CRC
cases) and 77% of AA. It has been shown that decreasing
the positivity threshold of FIT does not increase the de-
tection rate of ACN, and thus it is assumed that not all
CRCs can be detected by using FIT [34, 35].
A 3-fecal sample FIT regime was used in order to in-
crease the CRC detection rate, selecting the cut-off to
consider a sample as positive on the basis of the DOR.
This cut-off was lower than that used in the screening
program of average-risk asymptomatic patients in our
geographical area. The logistic regression analysis
showed that in addition to age, a maximum f-Hb level >
11 μg Hb/g faeces and the number of positive samples
(> 4 μg Hb/g faeces) were the variables associated with
the highest ORs to predict ACN. Noteworthy, having
three positive samples was associated with ACN with
the highest OR and C-Statistic. In contrast, no clinical
symptom or clinical presentation was independently as-
sociated with the risk of ACN after adjusting for age and
FIT variables. In fact, the low predictive value of clinical
symptoms has been previously reported [8, 10, 33]. In
addition to age and FIT variables, smoking increased
while a previous colonoscopy (in the last 5 years) de-
creased the risk.
Some previous studies had suggested the use of FIT
with other clinical variables or even only one-sample
FIT plus age and sex (FAST score) as a predictive tool of
CRC in symptomatic patients, showing more accuracy
than symptom-based referral criteria [11, 17]. NICE re-
ferral criteria for suspected CRC have a 68.2% sensitivity
and a 50.2% specificity for CRC detection and, actually,
these criteria cannot rule out CRC [11]. In the present
study, we showed that a COLONOTIF score > 10 points
has a sensitivity of 98% and a specificity of 53% to detect
CRC, and in this sense the NPV was 99.7% and the LR-
0.03. Although the specificity was not very high and a
Fig. 2 Comparison of the C-Statistic of the present 3-sample FIT model (COLONOFIT score) with the 1-sample FIT, age and sex test (FAST) score17
for ACN diagnosis in both the derivation and validation phase
Table 5 Probability of an individual classified based on its risk score (after applying the score derived from Phase 1 to the validation
cohort, Phase 2). The cut-off points were selected using the ‘AddFor’ algorithm (see methods)




> 20 0.34 0.34 0.32 0.34 (0.28; 0.39) 0.66 (0.51; 0.76)
10–20 0.76 0.16 0.07 0.76 (0.65; 0.86) 0.24 (0.14; 0.31)
≤10 0.90 0.09 0.01 0.90 (0.84; 0.97) 0.10 (0.01; 0.16)
*Control group: Non-AA, non-CCR
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low specificity is associated with unnecessary referrals, it
should be emphasized that a score > 10 allowed to
prioritize 50% of patients fulfilling NICE referral criteria,
detecting 98% of CRCs, and avoiding 50% of fast-track
colonoscopies. Furthermore, 70% of patients with CRC
had a score > 20 points, which was associated with a spe-
cificity of 90%. The present comparison shows that
COLONOFIT score classified patients a 3–4% better
Table 6 Accuracy of a positive risk score (> 10 points) to diagnose both ACN and CCR in the validation cohort (Phase II) and in the
derivation plus validation cohorts (Phase I + Phase II). Frequency of colonoscopy prioritization with the associated miss of either CRC
or AA cases for a Score > 10
PHASE II
ACN Control group (non-AA, non-CRC) Total
Score > 10 118 (47 CCR) 198 316
Score≤ 10 30 (2 CCR) 282 312
Total 148 480 628
ACN CRC
Sensitivity (%) 79 (72–85.4)† 96 (85–99)
Specificity (%) 58 (54.2–63) 52 (48–56)
PPV (%) 37 (32–42.7) 14.4 (11–19)
NPV (%) 90 (87–93.2) 99.3 (97–99.9)
Diagnostic OR 5.6 (3.6–8.7) 25.4 (6.1–106)
LR (+) 1.93 (1.7–2.2) 1.99 (1.8–2.2)
LR (−) 0.34 (0.25–0.48) 0.08 (0.02–0.30)
Prevalence (%) 23.6 7.8
Score≤ 10 N (%) Loss
Missed cases of CRC 2 4.1
Missed cases of AA 28 28.3
Score > 10 N (%) Prioritization
Prioritization 316 50.3




Score > 10 270 (114 CRC) 468 738
Score≤ 10 49 (2 CRC) 708 757
Total 319 1176 1495
ACN CRC
Sensitivity (%) 85 (80.3–88)† 98 (93–99.7)
Specificity (%) 60 (57.4–63) 53 (51–56)
PPV 36 (33.2–40) 15 (13–18)
NPV 93.5 (91.5–95) 99.7 (99–100)
Diagnostic OR 8.3 (6–11.5) 65.2 (16–265)
LR (+) 2.12 (1.95–2.31) 2.10 (1.98–2.24)
LR (−) 0.25 (0.20–0.33) 0.03 (0.008–0.13)
Prevalence (%) 21.3 7.76
Score≤ 10 N (%) Loss
Missed cases of CRC 2 1.7
Missed cases of AA 47 23
Score > 10 N (%) Prioritization
Prioritization 738 49.3
†95% CI
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than the FAST score in both the derivation and valid-
ation cohorts. Further studies on a direct comparison of
both scores are needed to assess if the 3–4% gain in clas-
sification could be offset by lower adherence (by submit-
ting 3 vs. 1 FIT).
Selecting patients attending primary care may prevent
a selection bias of patients with higher prior probability
of CRC [36]. The present study included mainly patients
referred by primary care for a fast-track colonoscopy
and, anyhow, the variable primary or secondary care re-
ferral was included in the analysis without showing sig-
nificant association with ACN. Thus, the derived risk-
score may guide primary care physicians in their referral
decisions for a fast-track colonoscopy. COLONOFIT
score allows risk-stratifying of patients in clinical prac-
tice to inform decision-making. Those patients with a
score > 20 (15% of the patients in the validation cohort)
had a risk of ACN of 66% (32% CRC, 34% AA) and
should be sent for a 2WW colonoscopy. In contrast,
those with a score ≤ 10 (50% of patients in the validation
cohort) had a risk of ACN of 10% (1% CRC, 9% AA),
and should be referred to either gastroenterology or
other appropriate clinic in secondary care or a colonos-
copy in the conventional slower referral route.
After developing the prediction model in the deriv-
ation cohort, its performance was evaluated in a differ-
ent cohort (validation cohort), collected using the same
protocol and outcome definitions and measurements,
but sampled from a later period. Such external validation
implies that for each individual in the new data set, out-
come predictions were made using the derived predictive
score [37, 38]. The performance of a predictive model is
typically worse when evaluated on samples independent
of the sample used to develop the model. In fact, in
phase 1 of the study all CRC patients and 82% of AA
had a score > 10; however, the performance characteris-
tics in the validation cohort remained good.
Prevalence of CRC in symptomatic patients of the
present study was near 8%, and that of ACN around
24%, which are figures much higher than those observed
in the CRC screening populations (typically, ACN has a
prevalence < 10% in that setting), and similar to other
previous studies [11, 17]. This reflects the need for a dif-
ferent diagnostic approach in the two settings, and in
this sense, lower cut-offs of FIT have been suggested for
symptomatic patients [7]. Results of the present study
suggest that using 3-sample FIT (on three different days)
is an additional diagnostic strategy that increases the
prior probability of ACN. The 3-sampling strategy for
FOBT was traditionally used for guaiac-based tests, and
was abandoned when introducing the more sensitive
FITs, and a meta-analysis showed that in average-risk
asymptomatic patients increasing the number of FIT
samples did not affect the pooled performance
characteristics of FITs for CRC [18]. It was concluded
that a 1-sample FIT regimen for CRC detection might
ultimately be desirable, given the importance of optimiz-
ing overall adherence in repeated rounds of biennial
testing for programmatic screening. However, several
studies have directly evaluated the effect of FIT sample
number on the diagnostic accuracy of FITs in average-
risk asymptomatic participants [19–21], and in symp-
tomatic patients [22, 23], suggesting that using either 2
or 3 tests provided the best discrimination for CRC.
Therefore, these data and the results of the present
study suggest that using 3-sample FIT may increase the
detection rate of ACN in patients with risk symptoms to
an acceptable number needed to scope.
Not all studies on statistical risk models to predict CRC
in people with symptoms included AA in addition to CRC.
However, it is widely accepted that CRC arises from the ad-
enoma-carcinoma sequence and so identification of pa-
tients with high-risk adenoma has the potential to reduce
future incidence of invasive CRC and prevent mortality. A
systematic review performed in 2016 included only two
models assessing CRC plus AA [13], both of which
reported only limited performance data and which have not
been externally validated [39, 40]. We think that the priority
of the model should be to identify both prevalent CRC and
the patients at high risk of developing CRC in the future,
and in this sense, the COLONOFIT score prioritizes symp-
tomatic patients to detect both CRC and AA.
This study has specific strengths that deserve to be
highlighted. All included patients had a colonoscopy
(even those with negative FIT); the best cut-off point of
FIT was selected on the basis of the results, using the
DOR value which maximizes the probability of ACN; a
3-sample FIT regime was evaluated to assess whether
the number of positive samples influenced the probabil-
ity of ACN; a face-to-face structured and detailed survey
was prospectively performed by a trained person; the ex-
ternal validation of the score was performed in a new
cohort selected later in time; the derived risk score is
ease of use, and all its components are readily available
to general practitioners. The study has also some limita-
tions. First, not all included patients were primary care
referrals, but as noted earlier, there was no significant
association with the referral origin, and all physicians
used the same criteria to refer a patient for a fast-track
colonoscopy that were reviewed by the case manager be-
fore inclusion. Second, the included patients fulfilled the
criteria for a fast-track colonoscopy; thus the use of the
predictive score cannot be generalized to patients with-
out these criteria without further studies. Finally, there
were missing data about iron status (patients were re-
ceiving iron supplements) without statistical significance
comparing the two study phases, which could have pre-
cluded finding a significant association.
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Conclusion
A risk-scoring system was derived and validated to
prioritize fast-track colonoscopies, which was shown to
be efficient, simple, and robust. Further external valid-
ation studies are needed to warrant the widespread rec-
ommendation of the model in clinical practice.
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